RxDoctor Payments Data

Ashleigh Terrell, NP

Nurse Practitioner · Royal Oak, MINPI 1669967618

Payments from drug & device makers

$584in general payments, 2019–2025

Across 20 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$111
  • Polynovo North America LLC$108
  • Catalyst Pharmaceuticals, Inc.$64
  • Neurelis, Inc.$63
  • Livanova USA, Inc.$48
  • Jazz Pharmaceuticals Inc.$33
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$56497%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.1$111
Polynovo North America LLC3$108
Catalyst Pharmaceuticals, Inc.2$64
Neurelis, Inc.3$63
Livanova USA, Inc.2$48
Jazz Pharmaceuticals Inc.2$33
Lundbeck LLC1$31
UCB, Inc.1$25
Otter Pharmaceuticals, LLC1$24
AbbVie1$22
EMD Serono, Inc.1$21
CSL Behring1$20
Aucta Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$584 in reported general payments places this provider in the 75th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$7,956
Medicare patients
40
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate20$63,255
BriviactBrivaracetam20$38,822
FycompaPerampanel20$26,323
XcopriCenobamate15$16,861
Lacosamide27$6,386
Clobazam30$2,548
Levetiracetam28$2,167
Zonisamide40$1,715
Lamotrigine ErLamotrigine13$1,569
Divalproex Sodium ErDivalproex Sodium13$1,004
Lamotrigine20$486
Topiramate32$374
Gabapentin12$121
Clonazepam11$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$25$38,82220 claims
SK Life Science, Inc.Xcopri$111$16,86115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →